Current Report · Items 2.02, 9.01 · 8-K

Codexis, Inc.

CDXSNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed May 7, 2026Accepted May 7, 2026, 4:15 PM EDTCIK 1200375Accession 0001193125-26-211956

Company context

Codexis® is a leading provider of high-performance enzymatic solutions for efficient and scalable therapeutics manufacturing. The company is currently developing its proprietary ECO Synthesis® Manufacturing Platform, an aqueous enzymatic process that may offer a scalable alternative to traditional solid phase organic synthesis of oligonucleotide manufacturing. Initially, Codexis is applying its technology to address the rapidly growing demand for RNAi therapeutics. Codexis’ unique enzymes can drive improvements such as higher yields, increased purity, reduced energy usage and waste generation, stereoisomer control of siRNA, and improved overall capacity in manufacturing at substantially lower capital requirements, all of which may lead to greater efficiency and reduced costs. In addition, the company supplies high-performance enzymes through its BioCatalysis business that are used in the manufacture of multiple commercially available small molecule therapeutics. For additional information, please visit https://www.codexis.com.

Current securities

CDXSNASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

Codexis, Inc. · 8-K · Filed 2026-05-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol: CDXS
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: duration_2026-05-07_to_2026-05-07

Dimensions: Not supplied

Accession 000119312526211956 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On May 7, 2026, Codexis, Inc. announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) d112205dex991.htm

EX-99.1 2 d112205dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Codexis Reports First Quarter 2026 Financial Results Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 7, 2026 - Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis® Manufacturing Platform enables control over phosphorothioate stereochemistry. Defined stereochemistry confers overall improved product quality and has the potential to deliver increased potency, a step beyond conventional manufacturing technologies,” said Alison Moore, PhD, President and Chief Executive Officer of Codexis. “We finished the first quarter in a strong financial position with $65.1 million in cash, which we believe remains on track to…

Open exhibit ↗

Get the free weekly BCS email.